Mapenterol hydrochloride

CAS No. 54238-51-6

Mapenterol hydrochloride( —— )

Catalog No. M28318 CAS No. 54238-51-6

Mapenterol hydrochloride is an agonist of β2-adrenergic receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 164 Get Quote
10MG 242 Get Quote
25MG 415 Get Quote
50MG 609 Get Quote
100MG 867 Get Quote
500MG 1737 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Mapenterol hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Mapenterol hydrochloride is an agonist of β2-adrenergic receptor.
  • Description
    Mapenterol hydrochloride is an agonist of β2-adrenergic receptor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    Adrenergic Receptor
  • Recptor
    Mitochondria
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    54238-51-6
  • Formula Weight
    361.231
  • Molecular Formula
    C14H21Cl2F3N2O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 25 mg/mL (69.21 mM助)
  • SMILES
    Cl.CCC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(=C1)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Zhang Z , Ju T , Ye J H , et al. CO2 = CO + O: Redox-Neutral Lactamization and Lactonization of C–H Bonds with CO2[J]. Synlett, 2017, 28(07):741-750.
molnova catalog
related products
  • Tiprenolol

    Tiprenolol?is a?beta adrenergic receptor antagonist.

  • Vilanterol trifenata...

    Vilanterol trifenatate is a long-acting agonist of β2-adrenoceptor (β2-AR) with inherent 24-hour activity(β2-AR, β1-AR and β3-AR pEC50s of 10.37, 6.98 and 7.36, respectively).

  • Dabuzalgron

    Dabuzalgron is an orally active selective alpha-1A adrenergic receptor agonist used to treat urinary incontinence. Dabuzaron prevents cardiotoxicity caused by doxorubicin by maintaining mitochondrial function.Dabuzaron treatment increased ERK phosphorylation in a dose-dependent manner with an EC50 of 4.8 μM.